Table 1 Cyberknife® publications for primary treatment of prostate cancer
Author | Dose scheme | No. of patients | Median follow-up (moths) | FFBF (in % by risk group) | Early toxicity in % | Late toxicity in % | Patients receiving ADT in % | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
low (l) | intermediate (i) | high (h) | GU | GI | GU | GI | |||||||||
G1 | G2 | G3 | G1 | G2 | G3 | G3 | G3 | ||||||||
Friedland et al. 2009[5] | 7 and 7.25 Gy × 5 | 112 | 24 | l,i,h: 97.3 | 0 | 1 | 19 | ||||||||
Bolzicco et al. 2010[17] | 7 Gy × 5 | 45 | 20 | l,i:100 | 36 | 11 | 0 | 24 | 24 | 0 | 22 | 0 | 38 | ||
Freeman et al. 2011[18] | 7 and 7.25 Gy × 5 | 41 | 60 | 92.7 | * | 25 | 0 | 0 | |||||||
Kang et al. 2011[19] | 8,8.5, and 9 Gy × 4 | 44 | 40 | 100 | 100 | 90.8 | n.A. | 14 | 0 | n.A. | 9 | 0 | 0 | 0 | 87 |
King et al. 2012[20] | 7.25 Gy × 5 | 67 | 32 | 94 (4-year) | 3 | 0 | 0 | ||||||||
McBride et al. 2012[21] | 7.25 and 7.25 Gy × 5 | 45 | 44 | 97.7 (3-year) | 59 | 19 | 0 | 31 | 7 | 0 | 2 | 5 | 0 | ||
Oliai et al. 2012[2] | 7,7.25 and 7.5 Gy × 5 | 70 | 31 | 100 | 94.7 | 77.1 | 56 | 19 | 4 | 17 | 4 | 0 | 3 | 0 | 33 |
Katz et al. 2013[4] | 7 and 7.25 Gy × 5 | 304 | 60 | 97.7 (3-year) | 90.7 | 74.1 | 72-75 | 4-5 | 0 | 75-76 | 4 | 0 | 2 | 0 | 19 |
Chen et al. 2013[3] | 7 and 7.25 Gy × 5 | 100 | 28 | 100 | 100 | 88 | 36 | 35 | 0 | 35 | 5 | 0 | 0 | <1 | 11 |
King 2013[6], pooled date | 7-7.25 Gy × 5 | 1100 | 36 | 95 | 83 | 78 | 14 | ||||||||